Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

GASTRIC CANCER

KEYNOTE-811: pembrolizumab in advanced HER2+ gastric cancer

Your institute does not have access to this article

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

References

Original article

  • Janjigian, Y. Y. et al. The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer. Nature 600, 727–730 (2021)

    CAS  Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Jordan Hindson.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Hindson, J. KEYNOTE-811: pembrolizumab in advanced HER2+ gastric cancer. Nat Rev Gastroenterol Hepatol 19, 79 (2022). https://doi.org/10.1038/s41575-022-00577-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41575-022-00577-y

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing